Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 6 SUPPL 2, 2008, Pages

  Riely, Gregory J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinases

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BIBW 2992; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXEL 7647; GEFITINIB; XL 647;

BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DYSGEUSIA; DYSPNEA; FATIGUE; GENE DELETION; GENE MUTATION; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; TREATMENT RESPONSE;

EID: 44649167010     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318174e96e     Document Type: Article

References (26)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
4. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9:485-495.
5. Politi K, Zakowski MF, Fan PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-1510.
6. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated Non-small cell lung cancer. N Engl J Med 2005;353:123-132.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
9. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 2004;22:1103-1109.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
11. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-3914.
12. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844.
13. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501.
14. Bean J, Brennan C, Shih JH, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937.
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Sciencexpress. Science 2007;316:1039-1043.
16. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
17. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-7670.
18. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
19. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and re-initiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-155.
20. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965.
21. Wong KK, Fracasso PM, Bukowski RM, et al. HKI-272, an irreversible pan ERBB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006;24:3018.
22. Gendreau SB, Ventura R, Keast P, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007;13:3713-3723.
23. Molina J, Wakelee H, Fehling J, et al. A Phase I dose-Escalation and Pharmacokinetic Study of XL647, A Novel Spectrum Selective Kinase Inhibitor, Administered Orally Daily to patients With Advanced Solid Malignancies AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA: 2007.Pp. B242.
24. Wakelee H, Adjei AA, Halsey J, et al. A phase I dose-escalation and pharmacokinetic (PK) studyof a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies. J Clin Oncol 2006;24:3044.
25. Rizvi N, Kris M, Miller VA, et al. A phase II study of XL647 in Non-small cell lung cancer patients enriched for presence of EGFR mutations, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA: 2007. Pp. B124.
26. Spicer J, Calvert H, Vidal L, et al. Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer with mutated EGFR, World Lung Cancer Congress. Seoul 2007; Pp. D7-02.